azalanstat has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
*Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amata, E; Barbagallo, I; Di Raimondo, F; Dichiara, M; Floresta, G; Intagliata, S; Marrazzo, A; Pittalà, V; Prezzavento, O; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Tibullo, D; Turnaturi, R; Vanella, L | 1 |
1 other study(ies) available for azalanstat and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heme Oxygenase-1; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation | 2018 |